Searchable abstracts of presentations at key conferences in endocrinology

ea0020p626 | Reproduction | ECE2009

Progesterone suppression of the male hypothalamo-pituitary gonadal axis is partially reversed by the progesterone antagonist mifepristone

McIntosh Joseph , Walley Ros , Wittke Baerbel , Sudworth David , Howe David

Background: Daily injection of progesterone in men is reported to suppress the pituitary LH response to GnRH challenge. We hypothesized that the progesterone nuclear hormone receptor antagonist mifepristone (RU486) would reverse these effects.Study design: Open–label randomised, three period crossover-over study in 12 healthy male subjects. Subjects were treated for 8 days with A/ progesterone 50 mg (IM) alone; B/ progesterone 50 mg + mifepristone 1...

ea0009p20 | Diabetes and metabolism | BES2005

Is ghrelin involved in BMI determination in patients with type 2 diabetes?

Garcia E , Gueorguiev M , Lecoeur C , Grossman A , Walley A , Froguel P , Korbonits M

Ghrelin is an orexigenic hormone, the endogenous ligand of the previously orphan growth-hormone-secretagogue receptor (GHS-R). Recently, it has been reported that pancreatic beta-cells are replaced by ghrelin-producing cells in a diabetic mice model implicating these genes as attractive candidates in the aetiology of type 2 diabetes (T2D) (PNAS;101:2924). The ghrelin gene is located at 3p25-26 and its cognate receptor at 3q26. We aimed to test for an association of these two g...